Beijing, Sept 4, 2026 — China’s Center for Drug Evaluation (CDE) has released for public comment a draft technical guideline governing specification changes to already-marketed traditional Chinese medicine (TCM) products, refining requirements set out in the agency’s existing trial guideline on pharmaceutical changes for marketed TCM drugs, with a comment window of one month from publication.
Consultation Snapshot
| Attribute | Detail |
|---|---|
| Document | Technical Guidelines for Research on Changes in Specifications of Listed TCM (Draft for Comments) |
| Issuing body | Center for Drug Evaluation (CDE), NMPA |
| Purpose | Detail specification-change requirements under the trial guideline on pharmaceutical changes for marketed TCM |
| Comment period | One month from publication (Sept 4, 2026) |
| Contact | Department of TCM and Ethnic Drug Pharmacy Affairs |
| zyyxzdyz@cde.org.cn (subject line must read “Specification Change”) |
Regulatory Context
In China’s post-approval change framework, “specifications” (规格) define a marketed drug’s dosage strength, unit-dose content or package configuration. For traditional Chinese medicines—spanning tablets, capsules, granules and oral liquids—specification changes are frequently needed to match clinical dosing practice, improve pediatric or geriatric usability, or align products with updated manufacturing scales. The draft guideline builds on the Technical Guidelines for Pharmaceutical Change Research of Listed TCM (Trial), which established a risk-based classification for post-approval changes to marketed Chinese patent medicines. The new document isolates specification changes for dedicated treatment, giving manufacturers a clearer evidentiary roadmap—covering pharmaceutical equivalence, quality consistency and, where warranted, clinical bridging studies—for filing such changes with provincial or national regulators.
Market Impact Analysis
The consultation addresses a long-standing friction point for China’s TCM sector: many marketed Chinese patent medicines carry legacy specifications that no longer fit modern clinical demand, yet holders have lacked granular guidance on the research package needed to change them. By detailing the requirements, CDE is effectively lowering the regulatory uncertainty around specification amendments—reducing the risk that holders over-invest in unnecessary bridging studies or under-invest and face rejection.
For TCM manufacturers, the guideline creates a practical pathway to refresh aging product portfolios: adjusting strengths to match evidence-based dosing, consolidating multiple specifications for supply-chain efficiency, or improving patient adherence through better-suited dosage configurations. The CDE frames the initiative explicitly as serving clinical medication needs and supporting the development of the TCM industry, consistent with Beijing’s broader policy push to modernize traditional Chinese medicine under dedicated state support measures.
The one-month comment window—standard for CDE technical guideline consultations—signals an intent to finalize the guideline on a near-term timeline, suggesting specification-change filings under the new framework could begin well before mid-2027.
Forward-Looking Statement
Industry participants are expected to submit feedback to the CDE’s TCM and Ethnic Drug Pharmacy department before the deadline in early October 2026, with the final guideline likely issued after the agency reviews and incorporates comments. Once adopted, the guideline should produce a measurable uptick in specification-change applications for marketed TCM products as holders align legacy specifications with current clinical practice. Market watchers will look for clarity in the final text on risk classification thresholds, the conditions triggering clinical bridging requirements, and consistency-evaluation standards—provisions that will determine how readily smaller TCM manufacturers can utilize the pathway. The draft also points toward continued refinement of China’s post-approval change system for traditional medicines, potentially extending to other change categories in future guideline iterations.-China Health Reform Pulse
Policy Source: https://www.cde.org.cn/main/news/viewInfoCommon/c5da4ee5650bdab08619259372885f93